Angiology

Idraparinux versus Standard Therapy for Venous Thromboembolic Disease

The long-acting factor X inhibitor idraparinux was compared with a standard antithrombotic regimen in two randomized trials, one for the treatment of deep venous thrombosis (DVT Study) and the other for the treatment of pulmonary embolism (PE Study).
Read more

 http://content.nejm.org/cgi/content/short/357/11/1094?rss=1&...

New England Journal of Medicine